NCT06583811

Brief Summary

Local anesthetics (LA) may be administered by injection (retrobulbar, peribulbar, subconjunctival, lid, or facial block) or by instillation (topical anesthesia), Considerable drawbacks of local anesthesia in these patients include the fact that a few patients can remain comfortable on an operating table for procedures that exceed two or three hours. Sedation may be helpful with LA to decrease the experience of discomfort, movement and anxiety, which may in turn positively influence hemodynamic parameters, patient satisfaction, and overall improve surgical safety. Sedatives used in eye surgeries include benzodiazepines, opioids, alpha-adrenoceptor agonists, and propofol.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 10, 2024

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

August 30, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 4, 2024

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2025

Completed
9 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 10, 2025

Completed
Last Updated

September 4, 2024

Status Verified

July 1, 2024

Enrollment Period

6 months

First QC Date

August 30, 2024

Last Update Submit

August 31, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Eye Movement

    Incidence of patients who are not moving their Eyes during long eye surgery

    from 0 hours to 4 hours after the procedure

Study Arms (2)

Group A: Remifentanil Group

ACTIVE COMPARATOR

About 35 Patients will receive Remifentanil bolus of 1 μg/kg over 30 seconds followed by a continuous infusion of 0.03-0.05 μg/kg/min.

Drug: Remifentanil

Group B: Remimazolam Group

ACTIVE COMPARATOR

About 35 Patients will receive remimazolam bolus of 0.2mg/kg followed by a continuous infusion of 0.3-0.5 μg/kg/h.

Drug: Remifentanil

Interventions

to compare remifentanil and remimazolam to limit patient movement during long-eye surgeries under local anesthesia.

Also known as: emimazolam
Group A: Remifentanil GroupGroup B: Remimazolam Group

Eligibility Criteria

Age40 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age \> 40 years.
  • Both sexes.
  • American Society of Anesthesiology (ASA) physical status I-III.
  • Undergoing long-eye surgeries under local anesthesia using peribulbar block with an expected surgical time of more than one hour.

You may not qualify if:

  • Patients on aspirin or anticoagulants.
  • Allergy to any study medication.
  • Drug abuse.
  • Uncontrolled hypertension.
  • Hyperthyroidism.
  • Frequent cough.
  • Impaired hearing.
  • Severe liver and kidney dysfunction.
  • Neurological or psychological disorders.
  • Partial or failed block.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Al-Azhar University hospitals

Cairo, Egypt

RECRUITING

MeSH Terms

Interventions

Remifentanil

Intervention Hierarchy (Ancestors)

PropionatesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Central Study Contacts

Ahmed M. Elnagar, M.D

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 30, 2024

First Posted

September 4, 2024

Study Start

July 10, 2024

Primary Completion

January 1, 2025

Study Completion

January 10, 2025

Last Updated

September 4, 2024

Record last verified: 2024-07

Locations